TransEnterix, Inc. (NYSEAMERICAN:TRXC) gapped down prior to trading on Monday . The stock had previously closed at $3.17, but opened at $3.10. TransEnterix shares last traded at $2.99, with a volume of 4724994 shares trading hands.

A number of research firms have recently weighed in on TRXC. Zacks Investment Research raised shares of TransEnterix from a “sell” rating to a “hold” rating in a research report on Friday, November 9th. BTIG Research reissued a “hold” rating on shares of TransEnterix in a research report on Tuesday, September 25th. Finally, LADENBURG THALM/SH SH raised shares of TransEnterix from a “neutral” rating to a “buy” rating and set a $5.00 target price for the company in a research report on Friday, November 9th.

TransEnterix (NYSEAMERICAN:TRXC) last released its earnings results on Thursday, November 8th. The medical instruments supplier reported ($0.06) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.07) by $0.01. The company had revenue of $5.40 million for the quarter, compared to the consensus estimate of $5.40 million. TransEnterix’s quarterly revenue was up 2850.8% on a year-over-year basis.

In related news, CFO Joseph P. Slattery sold 4,924 shares of the firm’s stock in a transaction that occurred on Tuesday, September 25th. The shares were sold at an average price of $7.03, for a total value of $34,615.72. Following the completion of the transaction, the chief financial officer now directly owns 4,924 shares of the company’s stock, valued at approximately $34,615.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director William N. Starling, Jr. sold 1,700,000 shares of the firm’s stock in a transaction that occurred on Tuesday, September 25th. The stock was sold at an average price of $6.40, for a total transaction of $10,880,000.00. Following the completion of the transaction, the director now directly owns 66,987 shares of the company’s stock, valued at $428,716.80. The disclosure for this sale can be found here. Insiders have sold a total of 2,909,224 shares of company stock valued at $18,271,761 over the last three months.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Amalgamated Bank bought a new position in TransEnterix in the 2nd quarter worth approximately $104,000. Global X Management Co LLC bought a new position in TransEnterix in the 2nd quarter worth approximately $11,212,000. Millennium Management LLC boosted its holdings in TransEnterix by 787.5% in the 1st quarter. Millennium Management LLC now owns 1,895,115 shares of the medical instruments supplier’s stock worth $3,222,000 after buying an additional 1,681,583 shares during the period. Ardsley Advisory Partners bought a new position in TransEnterix in the 2nd quarter worth approximately $109,000. Finally, Schwab Charles Investment Management Inc. bought a new position in TransEnterix in the 2nd quarter worth approximately $1,407,000.

ILLEGAL ACTIVITY WARNING: “TransEnterix (TRXC) Shares Gap Down to $3.10” was first reported by Daily Political and is the sole property of of Daily Political. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://www.dailypolitical.com/2018/11/20/transenterix-trxc-shares-gap-down-to-3-10.html.

About TransEnterix (NYSEAMERICAN:TRXC)

TransEnterix, Inc, a medical device company, engages in the research, development, and sale of medical device robotics to enhance minimally invasive surgery. The company offers Senhance System, a multi-port robotic surgery system, which allows up to four arms to control robotic instruments and a camera in Europe.

See Also: Cost of equity and a company’s balance sheet

Receive News & Ratings for TransEnterix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TransEnterix and related companies with MarketBeat.com's FREE daily email newsletter.